Telix Pharmaceuticals upsizes convertible bonds to US$600 million

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company successfully priced and increased its US$600 million convertible bond offering, up from US$550 million due to strong global investor demand.

What did Telix Pharmaceuticals report?

• US$600 million of 1.50% convertible bonds due 2031, upsized from US$550 million
• Initial conversion price set at US$13.85 (~A$19.55) per ordinary share, a 37.5% premium to reference price
• Interest payable quarterly, beginning 22 July 2026
• Concurrent repurchase of approximately A$637 million of existing A$650 million convertible bonds due 2029
• Settlement of the new issuance and repurchase expected on 22 April 2026

What else do investors need to know?

The offering attracted strong support from both existing and new eligible investors worldwide, reinforcing Telix’s reputation in the global capital markets. The convertible bonds will be convertible into fully paid ordinary shares, providing potential upside for bondholders if Telix’s share price performs well over the next five years.

As part of its refinancing, Telix is also repurchasing and cancelling over 85% of its outstanding 2029 convertible bonds. The company intends to redeem the remaining bonds, further streamlining its capital structure and reducing refinancing risk.

What did Telix Pharmaceuticals management say?

Managing Director and Group CEO Dr. Christian Behrenbruch, said:

The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.

What’s next for Telix Pharmaceuticals?

Looking ahead, Telix expects the completion of the bond issue and concurrent repurchase to enhance its capital management. These actions offer additional financial flexibility as the company pursues development and commercialisation of its radiopharmaceutical portfolio across multiple international markets.

Telix plans to continue investing in its late-stage clinical programmes and expansion, using the strengthened balance sheet to address unmet needs in oncology and rare diseases.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 41%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 15% over the same period.

View Original Announcement

The post Telix Pharmaceuticals upsizes convertible bonds to US$600 million appeared first on The Motley Fool Australia.

More reading

• Yancoal Australia announces $2.4bn Kestrel Coal Mine acquisition
• Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances
• 5 things to watch on the ASX 200 on Wednesday
• Qantas Airways flags higher fuel costs and capacity changes in FY26 update
• Cleanaway Waste Management trims FY26 outlook on fuel challenges

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.